| Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ... JAMA oncology 5 (7), 1008-1019, 2019 | 767 | 2019 |
| Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis NJ Short, S Zhou, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ... JAMA oncology 6 (12), 1890-1899, 2020 | 316 | 2020 |
| Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis HA Hill, X Qi, P Jain, K Nomie, Y Wang, S Zhou, ML Wang Blood advances 4 (13), 2927-2938, 2020 | 104 | 2020 |
| Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis NJ Short, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ... Leukemia 36 (12), 2817-2826, 2022 | 25 | 2022 |
| On Bayesian modeling of censored data in JAGS X Qi, S Zhou, M Plummer BMC bioinformatics 23 (1), 102, 2022 | 16 | 2022 |
| Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials Y Wang, S Zhou, X Qi, F Yang, MJ Maurer, TM Habermann, TE Witzig, ... Blood cancer journal 12 (1), 1, 2022 | 12 | 2022 |
| Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5: 1008–1019 Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ... | 8 | 2019 |
| Empirical use of causal inference methods to evaluate survival differences in a real‐world registry vs those found in randomized clinical trials HJ Lee, JB Wong, B Jia, X Qi, ER DeLong Statistics in medicine 39 (22), 3003-3021, 2020 | 5 | 2020 |
| Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis JF Wang, SR Hwang, Y Jiang, X Qi, S Zhang, SA Parikh, W Ding, ... Blood 140 (Supplement 1), 9882-9884, 2022 | 4 | 2022 |
| Meta-analysis of censored adverse events X Qi, S Zhou, CB Peterson, Y Wang, X Fang, ML Wang, C Shen arXiv preprint arXiv:2101.07934, 2021 | 2 | 2021 |
| P632: COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS S Hwang, J Wang, Z Tian, X Qi, Y Jiang, S Zhang, RC Godby, S Parikh, ... HemaSphere 7 (S3), e47546cf, 2023 | 1 | 2023 |
| Bayesian sparse modeling to identify high‐risk subgroups in meta‐analysis of safety data X Qi, S Zhou, Y Wang, C Peterson Research synthesis methods 13 (6), 807-820, 2022 | 1 | 2022 |
| Bayesian modeling of censored data with application to meta-analysis of immunotherapy trials X Qi | 1 | 2020 |
| Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies NJ Short, S Zhou, C Fu, D Berry, RP Walter, SD Freeman, CS Hourigan, ... Blood 136, 16-17, 2020 | | 2020 |
Shouhao ZhouAssociate Professor of Biostatistics, Pennsylvania State University確認したメール アドレス: pennstatehealth.psu.edu
